Skip to main content
OpenTrials
Completed

NCT Number: NCT06030219

Microbiome Effect of Omadacycline on Healthy Volunteers

The goal of this study is to assess microbiome changes associated with omadacycline vs. comparators (moxifloxacin or oral vancomycin). Using a phase I study design, healthy volunteers aged 18-40 years will be given a 10-day course of either omadacycline 450 mg days 1 and 2 followed by 300 mg PO once daily, moxifloxacin 400 mg once daily, or oral vancomycin 125 mg given four times daily. Stool will be collected at baseline, daily during therapy, and at two follow-up time periods (days 13-14 and days 30-32). DNA will be extracted from stool and used for qPCR biomass and microbial metagenomic experiments. Results from the study will provide definitive data on the microbiome effects of omadacycline versus comparator antibiotics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of Houston

Houston, Texas, 77204, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion. All volunteers will be considered healthy based on medical history

Exclusion. Patients will be excluded if they report any of the following:

  • Cardiovascular disease
  • Gastrointestinal disease
  • Hepatic or renal disease
  • Receipt of an antibiotic for at least three months prior to enrollment.
  • Receipt of a probiotic for at least a month prior to enrollment and during the entire study period.

Treatment and study plan

Omadacycline

Drug

10-day course

Vancomycin Pill

Drug

10-day course

moxifloxacin

Drug

10-day course

Primary outcomes

  1. Microbiome changes

    Time frame: During dosing and 30 day follow up period

    Metagenomic changes (16S rRNA) and qPCR for individual bacterial species

Sponsors and collaborators

Lead sponsor

University of Houston

Other

Collaborators

  • Paratek Pharmaceuticals Inc

Registry information

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Sep 8, 2023
Registry last updated
Mar 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.